Summary
The action of the dihydro prostacyclins, (6R)-PGI1 and (6S)-PGI1, was studied on the isolated guinea pig heart and bovine coronary artery strips. PGE2 and PGI2 were used as standards.
In the isolated guinea pig heart (6S)-PGI1 decreased the coronary perfusion pressure (CPP), myocardial force of contraction (MFC) and oxygen consumption (QO2). (6R)-PGI1 did not produce a significant change in these parameters. The ED50 (50% of maximum coronary dilation) was approximately 20 times higher for (6S)-PGI1 than for PGI2 or PGE2.
Treatment of the hearts with reserpine + tyramine abolished the (6S)-PGI1-induced decrease in MFC but not the decrease in the CPP. The same pattern of responses was seen with PGE2.
Bovine coronary artery strips were contracted by both (6S)-PGI1 and (6R)-PGI1, the ED50 (50% of maximum increase in tension) being 5 and 10 times higher than that for PGE2. The (6S)-PGI1-induced contraction was preceeded by a small relaxation, which, however, was much less than that seen after PGI2.
It is concluded that the hydration of the 5,6 double bound in the PGI2-like activity and generates PGE-like activity. The same biological activity of both dihydro prostacyclins in the isolated coronary artery strip but not in the intact coronary vascular bed leads to suggest that the sites of action in these systems are different.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armstrong, J. M., Dusting, G. J., Moncada, S., Vane, J. R.: Cardiovascular actions of prostacyclin (PGI2), a metabolite of arachidonic acid which is synthesized by blood vessels. Circ. Res. 43, Suppl. I, I-112–I-119 (1978)
De Deckere, E. A. M., Nugteren, D. H., Ten Hoor, F.: Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart. Nature 268, 160–163 (1977)
Dusting, G. J., Moncada, S., Vane, J. R.: Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachidonic acid. Prostaglandins 13, 3–15 (1977)
Fricke, U., Schrör, K.: On the specificity of binding of prostaglandins to coronary arteries — correlation to the biological response. Naunyn-Schmiedeberg's Arch. Pharmacol. 302, R35 (1978)
Hedqvist, P., Wennmalm, A.: Comparison of the effects of prostaglandins E1, E2 and F2a on the sympathetically stimulated rabbit heart. Acta Physiol. Scand. 83, 156–162 (1971)
Johnson, R. A., Morton, D. R., Kinner, J. A., Gorman, R. R., McGuire, J. R., Sun, F. F., Whittaker, N., Bunting, S., Salmon, J. A., Moncada, S., Vane, J. R.: The chemical characterization of prostaglandin X (Prostacyclin). Prostaglandins 12, 915–928 (1976)
Klaus, W., Krebs, R.: Eine verbesserte Methode zur gleichzeitigen Messung des Sauerstoffverbrauchs und der mechanischen Aktivität isolierter Muskelpräparate. Naunyn-Schmiedeberg's Arch. Pharmacol. 261, 93–101 (1968)
Krebs, R., Schrör, K.: Action of prostaglandin E2 on myocardial mechanics, coronary vascular resistance and oxygen consumption in the guinea pig isolated heart preparation. Br. J. Pharmacol. 55, 403–408 (1975)
Link, H.-B., Rösen, R., Schrör, K.: Prostacyclin (PGI2): a potent coronary dilating agent in the rat isolated heart. J. Physiol. 284, 106–107P (1978)
Moncada, S., Vane, J. R.: The discovery of prostacyclin (PGX): A fresh insight into arachidonic acid metabolism. Intersciences prostaglandin symposium, pp. 155–178. New York: Academic Press 1977
Moncada, S., Gryglewski, R., Bunting, S., Vane, J. R.: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263, 663–665 (1976)
Schrör, K., Moncada, S.: Effects of prostacyclin on coronary perfusion, heart rate and myocardial contractile force in isolated hearts of guinea pig and rabbit — comparison with prostaglandin E2. Prostaglandins (in press 1978)
Schrör, K., Moncada, S., Ubatuba, F. B., Vane, J. R.: Formation of prostacyclin (PGX) causes decrease in the coronary vascular resistance during application of arachidonic acid. Naunyn-Schmiedeberg's Arch. Pharmacol. 297, R 31 (1977)
Schrör, K., Moncada, S., Ubatuba, F. B., Vane, J. R.: Transformation of arachidonic acid and prostaglandin endoperoxide by the guinea pig heart. Formation of RCS and prostacyclin (PGX). Eur. J. Pharmacol. 47, 103–114 (1978)
Smith, J. B., Silver, M. J., Ingerman, C. M., Kocsis, J. J.: Prostaglandin D2 inhibits the aggregation of human platelets. Thrombosis Res. 5, 291–299 (1974)
Togna, G., Gandolfi, C., Andreoni, A., Fumagalli, A., Passarotti, C., Faustini, F., Patrono, C.: Inhibition of human platelet aggregation by stable analogs of prostacyclin. Pharmacol. Res. Commun. 9, 909–916 (1977)
Wennmalm, A.: Prostaglandin-mediated inhibition of noradrenaline release: III. Separation of prostaglandins released from stimulated hearts and analysis of their neurosecretion inhibitory capacity. Prostaglandins 15, 113–121 (1978)
Whittle, B. J. R., Broughton-Smith, N. K., Moncada, S., Vane, J. R.: The relative activity of prostacyclin (PGI2) and a stable analogue 6β-PGI1 on the gastrointestinal and cardiovascular systems. J. Pharm. Pharmacol. 30, 597–598 (1978)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schrör, K. The action of the dihydro derivatives of prostacyclin —(6R)-PGI1 and (6S)-PGI1 on the heart and the coronary vasculature. Naunyn-Schmiedeberg's Arch. Pharmacol. 306, 213–217 (1979). https://doi.org/10.1007/BF00507106
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00507106